Soluble IL6R represents a miR-34a target: Potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14026-14032

  Li, Huihui ^a   Rokavec, Matjaz ^a   Hermeking, Heiko ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colorectal cancer; Il 6r; Inflammation; miR 34a; STAT3

Indexed keywords

INTERLEUKIN 6 RECEPTOR; MICRORNA 34A; STAT3 PROTEIN; IL6R PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN; STAT3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IL6R GENE; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ANIMAL; CACO-2 CELL LINE; COLORECTAL TUMOR; FEEDBACK SYSTEM; GENETICS; HT-29 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEEDBACK; HT29 CELLS; HUMANS; MICRORNAS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84931076559     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4334     Document Type: Article

References (24)

1. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta- Huspenina J, Bader FG, Greten FR, and Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014; 124: 1853-1867.
2. Scheller J, and Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006; 195: 173-183.
3. Rossi JF, Lu ZY, Jourdan M, and Klein B. Interleukin-6 as a Therapeutic Target. Clin Cancer Res. 2015; 21: 1248-1257.
4. Nishimoto N, and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006; 2: 619-626.
5. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, and Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007; 11: 613-624.
6. Scheller J, Ohnesorge N, and Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006; 63: 321-329.
7. Chalaris A, Garbers C, Rabe B, Rose-John S, and Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011; 90: 484-494.
8. Rose-John S, Scheller J, Elson G, and Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80: 227-236.
9. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12: 613-626.
10. Rokavec M, Li H, Jiang L, and Hermeking H. The p53/miR-34 axis in development and disease. J Mol Cell Biol. 2014; 6: 214-230.
11. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, and Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011; 10: 4256-4271.
12. Siemens H, Jackstadt R, Kaller M, and Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 9: 1399-1415
13. Han Z, Zhang Y, Yang Q, Liu B, Wu J, Yang C, and Jiang Y. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget. 2015; epub
14. Ma W, Xiao GG, Mao J, Lu Y, Song B, Wang L, Fan S, Fan P, Hou Z, Li J, Yu X, Wang B, Wang H, et al. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget. 2015; 12: 10432-10444
15. Xu X, Chen W, Miao R, Zhou Y, Wang Z, Zhang L, Wan Y, Dong Y, Qu K, and Liu C. miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. Oncotarget. 2015; 6: 3988-4004.
16. Chen WY, Liu SY, Chang YS, Yin JJ, Yeh HL, Mouhieddine TH, Hadadeh O, Abou-Kheir W, and Liu YN. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 2015; 6: 441-457.
17. Wang AM, Huang TT, Hsu KW, Huang KH, Fang WL, Yang MH, Lo SS, Chi CW, Lin JJ, and Yeh TS. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget. 2014; 5: 5002-5016.
18. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Muller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sultmann H, et al. Role of miR- 34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget. 2014; 5: 462-472.
19. Agostini M, and Knight RA. miR-34: from bench to bedside. Oncotarget. 2014; 5: 872-881.
20. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, and Hermeking H. Detection of miR- 34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013; 19: 710-720.
21. Carstens JL, Lovisa S, and Kalluri R. Microenvironment-dependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch. J Clin Invest. 2014; 124: 1458-1460.
22. Matsuo K, Oka M, Murase K, Soda H, Isomoto H, Takeshima F, Mizuta Y, Murata I, and Kohno S. Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J Int Med Res. 2003; 31: 69-75.
23. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012; 8: 1237-1247.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-2007.